35 results on '"Guttman-Yassky, Emma"'
Search Results
2. Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
3. Minimal impact of IL-17 and IL-12/23 inhibition on SARS-CoV-2/COVID-19 antibody response in psoriasis patients
4. Alopecia Areata: Current Treatments and New Directions
5. IL-12/23-targeting in seborrheic dermatitis patients leads to long-lasting response
6. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
7. Baricitinib for the Treatment of Alopecia Areata
8. Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset
9. Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
10. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)
11. Obesity alters pathology and treatment response in inflammatory disease
12. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
13. Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV–VI
14. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata
15. Secukinumab responses vary across the spectrum of congenital ichthyosis in adults
16. Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
17. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
18. Tralokinumab for the Treatment of Atopic Dermatitis
19. Selective sweep for an enhancer involucrin allele identifies skin barrier adaptation out of Africa
20. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
21. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
22. Correction to: Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
23. Qualitative Assessment of Adult Patients’ Perception of Atopic Dermatitis Using Natural Language Processing Analysis in a Cross-Sectional Study
24. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
25. Correction to: JAK Inhibitors for Atopic Dermatitis: An Update
26. JAK Inhibitors for Atopic Dermatitis: An Update
27. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
28. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata
29. Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
30. The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment
31. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins
32. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
33. Systemic Therapy of Atopic Dermatitis: When, How, for How Long?
34. Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways
35. Perivascular leukocyte clusters are essential for efficient activation of effector T cells in the skin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.